The evolution of antiepileptic drug development and regulation
Tóm tắt
The early years of antiepileptic drug development were characterised by observation and serendipity, rather than a rational, targeted approach to drug development. Control of seizures was seen as the primary aim of therapy, with much less focus on safety and tolerability. However, experience with thalidomide in the 1960s brought safety to the fore, resulting in an era of much tighter regulatory control that still persists today. A direct consequence of this was an increased emphasis on the importance of evidence from randomised controlled trials. Despite the continuing reliance on randomised controlled trials for regulatory approval and the formulation of evidence-based guidelines, the modern era has seen an increasing acknowledgment of their limitations and the need for complementary sources of ‘real-world’ evidence. Such sources include registries and studies that are designed to provide a much broader assessment of a drug’s overall effectiveness; for example, by incorporating patient-reported outcomes to assess the effects of treatment on quality of life or functional status. Such changes reflect a more patient-centric approach to treatment, since it is now recognised that epilepsy can only be effectively managed if patients’ individual real-life needs are addressed, since a key to successful treatment is long-term compliance. Alongside these changes in approach, the modern era has witnessed important advances in antiepileptic drugs themselves, either through development of novel molecules, or targeted, structural improvements of older agents.
Tài liệu tham khảo
Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health 1999; 89: 98–101.
Azarbayjani F, Danielsson BR. Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxiareoxygenation damage. Teratology 2001; 63: 152–160.
Beghi E, Annegers JF, Collaborative Group for the Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia 2001; 42: 1422–1425.
Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41: 1276–1283.
Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet 1962; 1: 839–840.
Bonduelle M, Bouygues P, Sallou CI, Chemaly R. Expérimentation clinique de l’antiipileptique G 32 883 (Tegretol): résultats portant sur 100 cas observés en trois ans. Rev Neurol (Paris) 1964; 110: 209–215.
Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S. Doseresponse effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002; 48: 77–89.
Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31–41.
Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402–408.
Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet 2004; 364: 803–811.
Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236–242.
Chiron C, Dulac O, Pons G. Antiepileptic drug development in children: considerations for a revisited strategy. Drugs 2008; 68: 17–25.
Cramer JA, Smith DB, Mattson RH, Delgado Escueta AV, Collins JF. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983; 33(3 Suppl. 1): 26–37.
Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med 2003; 254: 105–113.
Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine—the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol 2005; 71: 325–328.
Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J 1954; 1: 1451–1455.
Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65: 1976–1978.
Duncan S. Teratogenesis of sodium valproate. Curr Opin Neurol 2007; 20: 175–180.
Dupont S, Striano S, Trinka E, et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a noncomparative, open-label study (ZEUS). Acta Neurol Scand, 2009 [Epub ahead of print].
Durelli L, Massazza U, Cavallo R. Carbamazepine toxicity and poisoning. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp 1989; 4: 95–107.
Faught E, Ayala R, Montouris GG, Leppik IE, Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–1779.
Felbamate (Felbatol®) Prescribing Information. Updated 06/2008. Available at: http://www.felbatol.com/pi.pdf (Accessed 3 February 2010).
Fertig EJ, Mattson RH. Carbamazepine. In: Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook, Vol.2. Philadelphia: Lippincott Williams & Wilkins, 2007: 1543–1556.
French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999; 52: 1540–1545.
French JA, Kanner AM, Bautista J, et al., Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252–1260.
Friedlander WJ. The rise and fall of bromide therapy in epilepsy. Arch Neurol 2000; 57: 1782–1785.
Garofalo E. Obtaining pediatric indications for new anti-epileptic drugs: how and when. Epilepsy Res 2006; 68: 38–42.
Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000; 55: 1106–1109.
Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004; 62: 23–27.
Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094–1120.
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70: 1950–1958.
GlaxoSmithKline and Valeant Pharmaceuticals International. Retigabine Regulatory Update. Press release, issued 02 November 2009. Available at: http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10122.htm (Accessed 10 February 2010).
Gowers WR. Epilepsy and other chronic convulsive diseases: their causes, symptoms, & treatment. London: Churchill, 1881.
Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989; 27(Suppl. 1): 43S–45S.
Hashizume Y, Hanada T, Ogasawara A, Ueno M, Nishizawa Y. Pharmacological profile of E2007: broad-spectrum anticonvulsant activity in rodent models of epilepsy. Poster presented at Neuroscience 2007, San Diego, CA, USA, 3–7 November, 2007.
Hashizume Y, Hanada T, Ogasawara A, Ueno M, Nishizawa Y. Anticonvulsant activity of perampanel, a selective AMPA receptor antagonist, in rodent models of epileptic seizure. Poster presented at the 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, USA, 12–19 April, 2008.
Hauptmann A. Luminal bei Epilepsie. Münch Med Wochenschr 1912; 59: 1907–1909.
Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44–50.
Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300.
Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 1986; 2: 340–345.
Johnson JP. Acquired craniofacial features associated with chronic phenytoin therapy. Clin Pediatr (Phila) 1984; 23: 671–674.
Kanner AM. Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol 2008; 21: 190–194.
Krall RL, Penry JK, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: I. History and a program for progress. Epilepsia 1978; 19: 393–408.
Krauss G, Biton V, Klapper J, et al. Determination of tolerability, safety, and efficacy of perampanel, a selective AMPA receptor antagonist, as adjunctive therapy in subjects with refractory partial epilepsy. Epilepsia 2009; 50(Suppl. 10): 103. Abstract p476.
Krishnamurthy KB. Pregnancy and epilepsy: update on pregnancy registries. Curr Treat Options Neurol 2008; 10: 246–252.
Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255–1260.
Labar DR. Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study. Neurology 2002; 59(6 Suppl. 4): S38–43.
Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716–722.
Laxer KD. Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. West J Med 1994; 161: 309–314.
Lenz W. Klinische Missbildüngen nach Medikament: einnahme Während der Gravidität? Dtsch Med Wochenschr 1961; 86: 2555–2565.
Liu Y, Yohrling GJ, Wang Y, et al. Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res 2009; 83: 66–72.
Loiseau PJ. Clinical experience with new antiepileptic drugs: antiepileptic drugs in Europe. Epilepsia 1999; 40(Suppl. 6): S3–S8.
Lorge M. Klinische Erfahrungen mit einem neuen Antiepilepticum, Tegretol (G 32 883) mit besonderer Wirkung auf die epileptische Wesenveränderung. Schweiz Med Wochenschr 1963; 93: 1042–1047.
Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 2007; 17: 413–425.
Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008; 154: 1662–1671.
Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–151.
Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327: 765–771.
McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358–1363.
Merritt H, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J Am Med Soc 1938; 111: 1068–1073.
Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997; 38: 1026–1031.
Monaghan EP, McAuley JW, Data JL. Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin Invest Drugs 1999; 8: 1663–1671.
Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003; 54: 153–161.
National for Health and Clinical Excellence (NICE). The diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE Clinical Guideline 20 (CG20), October 2004. Available at: http://www.nice.org.uk/nicemedia/pdf/CG020fullguideline.pdf (Accessed 3 February 2010).
Nohria V, Giller E. Ganaxolone. Neurotherapeutics 2007; 4: 102–105.
Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968–3977.
Pearce JM. Bromide, the first effective antiepileptic agent. J Neurol Neurosurg Psychiatry 2002; 72: 412.
Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695–714.
Prince HK, Conn PJ, Blackstone CD, Huganir RL, Levey AI. Down-regulation of AMPA receptor subunit GluR2 in amygdaloid kindling. J Neurochem 1995; 64: 462–465.
Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med 2008; 5: e166.
Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979; 4: 153–169.
Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273–294.
Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000; 282: 73–76.
Sackellares JC, Ramsay RE, Wilder BJ, Browne 3rd TR, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004; 45: 610–617.
Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf 2004; 3: 655–665.
Schindler W, Häfliger F. Über Derivate des Iminodibenzyls. Helv Chim Acta 1954; 37: 472–483.
Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73.
Seeruthun R, Yeates A, Ashworth S. A European registry of antiepileptic drug use in patients with Lennox-Gastaut syndrome. Epilepsia 2009; 50 (Suppl. 10): 35. Abstract p140.
Shah RR, Griffin JP. Regulation of human medicinal products in the European Union. In: Griffin JP, O’Grady J, eds. The Textbook of Pharmaceutical Medicine. Massachusetts: Blackwell, 2006: 489–534.
Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179–1186.
Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909–1958. Epilepsia 2009a; 50(Suppl. 3): 69–92.
Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959–2009. Epilepsia 2009b; 50(Suppl. 3): 93–130.
ai]Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005; 128: 7–17.
Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769–782.
Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002; 40: 789–801.
Tohen M, Castillo J, Cole JO, Miller MG, de los Heros R, Farrer RJ. Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry 1991; 52: 496–498.
Vajda FJ, Hitchcock A, Graham J, O’Brien T, Lander C, Eadie M. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47: 468–474.
Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007; 9: 353–412.
Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007; 48: 1318–1327.
Williams SWD. On the Efficacy of the bromide of potassium in epilepsy and certain psychical affections. Br J Psychiatry 1866; 11: 598–602.
Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003; 28: 126–129.